Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

9823	Companies
197209	Keywords
128289	Articles
104885	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 09/05/2025 at 07:00, 5 months 4 days ago

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRIEF

published on 08/12/2025 at 07:05, 5 months 28 days ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
BRIEF

published on 08/12/2025 at 07:05, 5 months 28 days ago

Newron lance l'étude de phase III ENIGMA-TRS pour la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Étude De Phase III Thérapie TRS
PRESS RELEASE

published on 08/12/2025 at 07:00, 5 months 28 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 5 months 29 days ago

L'Evenamide de Newron Pharmaceuticals s'avère prometteur dans le traitement de la schizophrénie

Newron Pharmaceuticals Traitement De La Schizophrénie Recherche Sur L'évenamide Modulation Du Glutamate Étude De Neuropsychopharmacologie
BRIEF

published on 08/11/2025 at 07:05, 5 months 29 days ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 5 months 29 days ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRIEF

published on 05/12/2025 at 07:05, 8 months 28 days ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
BRIEF

published on 05/12/2025 at 07:05, 8 months 28 days ago

Le programme ENIGMA-TRS de phase III de Newron approuvé pour le traitement de la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Schizophrénie Résistante Au Traitement Modulation Glutamatergique
PRESS RELEASE

published on 05/12/2025 at 07:00, 8 months 28 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program

Accesswire

Published on 02/09/2026 at 15:00, 26 minutes ago

Gungnir Resources Inc. Announces Management And Board Changes
Published on 02/09/2026 at 14:15, 1 hour 11 minutes ago

White Gold Corp. Appoints Seasoned Mining Executive Donovan Pollitt as Strategic Advisor
Published on 02/09/2026 at 14:00, 1 hour 26 minutes ago

Paymetrex Secures First U.S. License Payment
Published on 02/09/2026 at 14:00, 1 hour 26 minutes ago

Geophysics Converge Ahead of Colosseum Deeper Drill Program
Published on 02/09/2026 at 13:00, 2 hours 26 minutes ago

Eagle Plains' Partner Refined Energy Corp. Mobilizes Geophysical Team to the Dufferin West Project, Saskatchewan

View all ACCESSWIRE

EQS Group

Published on 02/09/2026 at 14:52, 34 minutes ago

Aroundtown SA: Release of a capital market information
Published on 02/09/2026 at 14:20, 1 hour 6 minutes ago

EQS-Adhoc: Borussia Dortmund reports preliminary figures for the first half (H1) of the 2025/2026 financial year
Published on 02/09/2026 at 13:50, 1 hour 36 minutes ago

Cango Inc. Releases 2025 Letter to Shareholders
Published on 02/09/2026 at 13:35, 1 hour 51 minutes ago

DeFi Technologies launches the DEFT Valour Investment Opportunity Index
Published on 02/09/2026 at 13:32, 1 hour 53 minutes ago

Hapag-Lloyd publishes preliminary business figures for 2025

Les Echos

Published on 02/09/2026 at 14:49, 37 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/09/2026 at 10:40, 4 hours 45 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 02/09/2026 at 08:30, 6 hours 56 minutes ago

THERMADOR GROUPE : Plan to separate the roles of chairman and chief executive officer
Published on 02/09/2026 at 08:30, 6 hours 56 minutes ago

THERMADOR GROUPE : Projet de séparation des mandats de président et directeur général
Published on 02/09/2026 at 08:00, 7 hours 26 minutes ago

Eiffage renforce son expertise dans le secteur du froid industriel avec une prise de participation majoritaire dans l’entreprise française Quercy Réfrigération

View all LES ECHOS COMFI WIRE